Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy with Antibody Platforms

This activity is sponsored by PVI, PeerView Institute for Medical Education.

This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Release Date

May 9, 2024

Expiration Date

May 2, 2025

Media

Enduring Material

Time to Complete Activity

60 minutes

Activity Description

The advent of innovative antibody platforms, including CD38 and BCMA-targeted strategies, has radically transformed modern management of multiple myeloma (MM), offering patients a broader spectrum of therapeutic choices along their treatment journey. For hematology-oncology pharmacists, the advent of innovative antibody platforms presents a clear opportunity to ensure effective care coordination, patient education, and the proper administration of highly effective treatment options.

In this recording from the 2024 Hematology/Oncology Pharmacy Association (HOPA) 20th Annual Conference, a panel of myeloma experts exchange ideas and present clinical cases to illustrate the central role that hematology-oncology pharmacists play in delivering care with antibody platforms in multiple myeloma. Each “Clinical Consult” case conversation will link to the latest evidence supporting CD38, BCMA, and non-BCMA antibody strategies and provide guidance on how pharmacists can lead the integration of innovative antibody platforms across the spectrum of myeloma care. Don’t miss this opportunity to learn from leading experts and sharpen your skills in the context of multiple myeloma care!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms, efficacy and safety evidence, and practice guidelines supporting the treatment roles of CD38, BCMA, and non-BCMA antibody platforms in MM
• Develop pharmacist-guided team protocols for the integration and safe administration of antibody platforms across the spectrum of MM
• Address practical aspects of team care when using antibody platforms, including potential drug interactions, dosing, safety, patient/staff counseling, and managing supportive therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Professor, Hematology/Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen; EMD Serono; ERASCA, INC.; Janssen Pharmaceuticals, Inc.; and Tubulis.

Grant/Research Support from ADC Therapeutics SA; Amgen; Bayer Corporation; Bristol Myers Squibb; GlaxoSmithKline; Hutchison Medipharma Ltd.; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences Inc.; Meryx Inc.; MorphoSys AG; Pfizer; Ranok Therapeutics Co. Ltd.; and Xencor, Inc. Research funding to institution.

Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center
Kansas City, Kansas

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Bristol Myers Squibb; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals; Pfizer; and Sanofi.

Faculty/Planner
James Davis, PharmD, BCOP
MUSC Hollings Cancer Center
Clinical Pharmacy Specialist – Malignant Hematology
Assistant Professor – MUSC College of Pharmacy
Charleston, South Carolina

James Davis, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:

Speaker for Janssen Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-017-H01-P
Type of Activity: Application

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView